etanercept sold brand name enbrel among others biologic medical product used treat autoimmune diseases interfering tumor necrosis factor tnf soluble inflammatory cytokine acting tnf inhibitor us food drug administration fda approval treat rheumatoid arthritis juvenile idiopathic arthritis psoriatic arthritis plaque psoriasis ankylosing spondylitis tumor necrosis factor alpha tnfα master regulator inflammatory immune response many organ systems autoimmune diseases caused overactive immune response etanercept potential treat diseases inhibiting etanercept fusion protein produced recombinant dna fuses tnf receptor constant end antibody first developers isolated dna sequence codes human gene soluble tnf receptor receptor binds tumor necrosis factoralpha second isolated dna sequence codes human gene fc end immunoglobulin third linked dna tnf receptor dna fc finally expressed linked dna produce protein links protein tnf receptor protein prototypic fusion protein first synthesized shown highly active unusually stable modality blockade tnf vivo early bruce beutler academic researcher university texas southwestern medical center dallas investigators also patented selling rights use immunex seattle biotechnology company acquired amgen large molecule molecular weight kda binds tnfα decreases role disorders involving excess inflammation humans animals including autoimmune diseases ankylosing juvenile rheumatoid arthritis psoriasis psoriatic arthritis rheumatoid arthritis potentially variety disorders mediated excess tnfα world health organizations list essential united states etanercept indicated european union etanercept indicated treat american physician edward tobinick attempted use etanercept treat chronic neurological dysfunction stroke brain issued foreign patents writing sciencebased medicine steven novella said unethical physicians practice outside area competence expertise tobinick sued novella response treatment american academy neurology advise insufficient evidence determine effectiveness treatment may associated adverse outcomes high may us food drug administration fda placed black box warning etanercept due number serious infections associated serious infections sepsis including fatalities reported use etanercept including reactivation latent tuberculosis hepatitis b injection site reactions redness pain common occurring approximately etanercept reduces effect naturally present tnf hence tnf inhibitor functioning decoy receptor binds tumor necrosis factoralpha tnfα cytokine produced lymphocytes macrophages two types white blood cells mediates immune response attracting additional white blood cells sites inflammation additional molecular mechanisms initiate amplify inflammation inhibition action etanercept reduces inflammatory response especially useful treating autoimmune diseases two types tnf receptors found embedded white blood cells respond tnf releasing cytokines soluble tnf receptors used deactivate tnf blunt immune response addition tnf receptors found surface virtually nucleated cells red blood cells nucleated contain tnf receptors surface etanercept mimics inhibitory effects naturally occurring soluble tnf receptors difference etanercept fusion protein rather simple tnf receptor greatly extended halflife bloodstream therefore profound longlasting biologic effect naturally occurring soluble tnf etanercept made combination two naturally occurring soluble human tnf receptors linked fc portion effect artificially engineered dimeric fusion etanercept complex molecule containing nglycans oglycans disulfide bridge first etanerceptrelated patent filed immunex september fusion protein developed bruce beutler academic researcher university texas southwestern medical center dallas colleagues patented licensed rights another patent fusion protein technology brian seed massachusetts general hospital licensed immmunex etanercept approved use united states november etanercept approved use european union february us retail price etanercept risen time cost etanercept per month per cost exceeded per survey international federation health plans ifhp found average us cost etanercept per month per ifhp report also found wide variation prices charged various us health plans per month percentile per month etanercept expensive us average monthly costs surveyed nations ranged switzerland canada compared average monthly cost per month amgen sells etanercept within us canada pfizer inc sells drug outside us sales within us canada billion sales etanercept outside us canada billion patent etanercept set expire october united states second patent granting exclusivity another years extension seemed unlikely generic would available biologic etanercept subject different laws applicable chemical formulations many countries permit manufacture generic biologics however european union united states biologics price competition innovation act place system approve generic biologics biosimilars requires mandatory clinical testing periodic april indian pharma major cipla made announcement launching first biosimilar etanercept india brand name etacept treatment rheumatic january benepali approved use european february lifmior approved use european withdrawn market february june erelzi approved use european march etanercept biosimilar yl biologics approved may nepexto approved use european rymti etera approved medical use australia october httpsenwikipediaorgwikietanercept